In partnership with
The Bottom Line Upfront 💡
Novo Nordisk $NVO ( ▼ 2.15% ) pioneered the blockbuster GLP-1 obesity and diabetes drugs but is losing market share to Eli Lilly despite operating in a rapidly expanding market. The company remains a cash-generating machine with deep expertise, but faces mounting competitive and pricing pressures that could significantly impact future returns.
Sponsorship
Want to get the most out of ChatGPT?
ChatGPT is a superpower if you know how to use it correctly.
Discover how HubSpot's guide to AI can elevate both your productivity and creativity to get more things done.
Learn to automate tasks, enhance decision-making, and foster innovation with the power of AI.
Strata Layers Chart
Layer 1: The Business Model 🏛️
Think of Novo Nordisk as the world's pharmacy for people struggling with their weight and blood sugar. This Danish company has been in the diabetes game since 1925 (yes, they're older than sliced bread), and they've basically turned helping people manage chronic diseases into an art form.
What They Actually Do: Novo Nordisk makes and sells medications that help people with diabetes control their blood sugar and help people with obesity lose weight. Their secret sauce? They're absolute wizards at something called GLP-1 receptor agonists - fancy drugs that work like your body's natural hormones to control appetite and blood sugar.
The Money Makers:
Ozempic® for diabetes: Their crown jewel, pulling in DKK 127 billion ($18.1B) in 2025 ↗️
Wegovy® for obesity: The weight-loss superstar with DKK 79 billion ($11.3B) and 36% growth ↗️
Traditional insulins: The reliable workhorses like NovoLog and Tresiba
Rare disease treatments: Smaller but profitable niche products for growth disorders and blood clotting issues
How They Measure Success:
Market share in the GLP-1 category (spoiler alert: they're losing ground to Eli Lilly)
Manufacturing capacity utilization (they're building factories like there's no tomorrow)
Pipeline progression (10+ drugs in Phase 3 trials)
Geographic expansion (170 countries and counting)
The company operates like a global pharmaceutical machine with massive production facilities in Denmark, the US, France, China, and Brazil. They're currently spending a mind-boggling DKK 155 billion ($22B) on new factories through 2029 - that's like building a small city dedicated to making diabetes and obesity drugs.
Key Takeaway: Novo Nordisk is essentially the world's specialist clinic for diabetes and obesity, turning chronic disease management into a $33B+ annual business through innovative hormone-based treatments.
Layer 2: Category Position 🏆
Novo Nordisk finds itself in a classic David vs. Goliath situation, except both David and Goliath are pharmaceutical giants, and they're fighting over who gets to help millions of people lose weight and manage diabetes.
The Main Rival: Eli Lilly is Novo's primary nemesis, and frankly, Lilly has been eating Novo's lunch lately. In 2025, Lilly's competing GLP-1 products overtook both Ozempic (for diabetes) and Wegovy (for obesity) as the #1 prescribed medications in the US ↘️. Ouch.
Market Dynamics: The obesity market is absolutely exploding - it literally doubled by volume in 2025 alone ↗️. With 800+ million people living with obesity globally and diabetes cases projected to hit 780 million by 2045, there's plenty of pie to go around. The problem? Novo is losing market share even as the market grows.
Recent Competitive Challenges:
Lost US market leadership in both key GLP-1 categories ↘️
Facing generic competition on older products like Victoza (sales dropped from DKK 5.5B to DKK 3.0B) ↘️
Dealing with illegal compounding pharmacies making knockoff versions of their drugs
Patent cliff approaching in 2032 for their most valuable products
The Silver Lining: Novo still has deep expertise in protein engineering, a global manufacturing footprint, and a pipeline of next-generation combination therapies. Plus, they're backed by patient capital from the Novo Nordisk Foundation, which means they can think long-term while competitors worry about quarterly earnings.
Key Takeaway: Novo Nordisk is the #2 player in a rapidly growing market, but they're currently losing ground to Eli Lilly despite having pioneered many of the breakthrough treatments.
Layer 3: Show Me The Money! 📈
Novo Nordisk's financial story is like watching a successful restaurant deal with a new competitor moving in next door - still making great money, but having to work harder for every customer.
Revenue Breakdown:
Obesity & Diabetes Care: 90%+ of total sales (the main event)
Rare Disease: ~10% of sales (smaller but steady)
Geographic Split: US is the biggest market, followed by China, Canada, Japan, and Europe
The Growth Story: Revenue growth has cooled from the red-hot 25% in 2024 to a more modest 6.4% in 2025 ↘️. This isn't necessarily bad - it's more like the market is maturing and competition is intensifying. The company is still generating massive cash flows, evidenced by their ability to fund that DKK 155 billion factory expansion entirely from operations.
Margin Pressures: Here's where things get spicy. US payers (insurance companies and pharmacy benefit managers) are demanding bigger rebates, and average prices after rebates actually declined in 2025 ↘️. The company is also dealing with:
Medicare Part D price negotiations (negotiated prices kick in 2027)
Increasing exposure to high-rebate government programs
Rising manufacturing costs from capacity expansion
The Cash Flow Machine: Despite competitive pressures, Novo generates enough cash to:
Fund massive capital expenditures without borrowing
Pay dividends to shareholders
Make billion-dollar acquisitions (like the $4.7B Akero deal)
Cost Structure:
R&D spending: 15-17% of sales (and growing) ↗️
Manufacturing: Massive ongoing investments in capacity
Sales & Marketing: Global commercial operations across 170 countries
Key Takeaway: Novo Nordisk is still a cash-generating machine, but margin pressures from competition and payer pushback are starting to squeeze profitability in their core markets.
Layer 4: Long-Term Valuation (DCF Model) 💰
The Verdict: Fairly Valued to Slightly Undervalued
Scenario | Fair Value | vs Current Price ($46.40) |
|---|---|---|
Conservative | $23.03 | -50.4% ↘️ |
Optimistic | $46.64 | +0.5% ↗️ |
Market-Based | $40.12 | -13.5% ↘️ |
Key Valuation Drivers:
Competition intensity: Can Novo regain market share or will Eli Lilly continue dominating?
Pricing pressure: How much will payers squeeze margins going forward?
Pipeline success: Will next-gen combination therapies restore competitive advantage?
The wide valuation range ($23-$47) reflects massive uncertainty around competitive dynamics. If Novo successfully defends its market position and launches breakthrough combination therapies, the stock could hold current levels. If they continue losing share to Eli Lilly while facing pricing pressure, there's significant downside risk.
Recommendation: Novo Nordisk is a high-quality company facing a challenging competitive transition - suitable for investors who believe in the company's innovation capabilities and long-term market opportunity, but not for those seeking near-term growth momentum.
Layer 5: What Do We Have to Believe? 📚
Bull Case 🚀
Innovation Leadership: Novo's pipeline of combination therapies (Cagrisema, IcoSema) will differentiate them from Eli Lilly and restore market leadership
Market Expansion: The obesity treatment market will continue exploding, with Novo capturing meaningful share through geographic expansion and new formulations (like oral Wegovy)
Manufacturing Scale: Their massive $22B factory investment will create cost advantages and supply reliability that competitors can't match
Bear Case 🐻
Permanent Share Loss: Eli Lilly's competitive products are simply better, and Novo will continue losing market share in both diabetes and obesity
Pricing Pressure: US payers will continue squeezing margins, while government price negotiations expand beyond Medicare to other programs
Patent Cliff: When key patents expire in 2032, generic/biosimilar competition will devastate profitability on their most important products
The Bottom Line: Novo Nordisk is a world-class pharmaceutical company caught in a difficult competitive transition. They pioneered the GLP-1 revolution but are now fighting to maintain relevance against a formidable competitor. Success depends on their ability to innovate faster than Eli Lilly while managing pricing pressures and preparing for eventual patent expirations. It's a high-stakes game with massive rewards for winners and significant risks for losers.
What to Watch 👀
Market Share Metrics: Track monthly prescription data for Ozempic vs. Lilly's Mounjaro in diabetes, and Wegovy vs. Lilly's Zepbound in obesity. If Novo's share continues declining below 40% in either category, that's a red flag 🚩
Manufacturing Milestones: Watch for updates on their massive factory expansion program. Delays or cost overruns could signal execution problems, while on-time delivery would demonstrate operational excellence.
Pipeline Progress: Key regulatory approvals to watch include Cagrisema (combination therapy), IcoSema (insulin + GLP-1), and oral Wegovy expansion. These could be game-changers for competitive positioning.
Pricing Developments: Monitor quarterly commentary on US pricing pressure, rebate trends, and any expansion of government price negotiations beyond Medicare Part D.
340B Resolution: The company expects to recognize $4.2B in previously constrained revenue in Q1 2026 from the 340B drug pricing dispute resolution - this should provide a nice one-time boost to results.
AI-written, human-approved
Disclaimer: This guide is for informational purposes only and does not constitute financial advice, investment recommendations, or an offer or solicitation to buy or sell any securities. The information contained in this report has been obtained from sources believed to be reliable, but StrataFinance does not guarantee its accuracy, completeness, or timeliness.